Savient Pharmaceuticals, Inc. (SVNTQ) - OTCPK - Limited
SVNTQ is defunct.
  • Aug. 14, 2013, 12:43 PM
    • Savient Pharmaceuticals (SVNT -5%) slips after its Q2 misses EPS estimates on a greater than anticipated loss.
    • Net revenues increased by 44% Y/Y to $2.1M, primarily driven by higher KRYSTEXXA net sales.
    • KRYSTEXXA net sales rose 52% Y/Y, substantially due to the impact of product price increases and to a lesser extent an increase in sales volume.
    • The selling price of KRYSTEXXA increased by approximately 134% from the original list price of $2,300 per vial to the current list price of $5,390 per vial, effective May 17, while 2,058 vials of KRYSTEXXA were sold, an increase of 9% Y/Y.
    | Aug. 14, 2013, 12:43 PM
  • Jun. 20, 2013, 4:43 PM

    Savient Pharmaceuticals (SVNT) announces the formation of an Office of the President, consisting of Richard Crowley, who will serve as Co-President and COO, John P. Hamill, who will serve as Co-President and CFO, and Philip K. Yachmetz, who will serve as Co-President and Chief Business Officer. Savient also says that Louis Ferrari, President, CEO, and Director, is leaving the Company to pursue other interests, effective immediately. Shares -4.3% AH.

    | Jun. 20, 2013, 4:43 PM
  • Jun. 13, 2013, 1:52 PM

    Savient Pharmaceuticals (SVNT +12.7%) increases the price per vial for Krystexxa to $5,390 for orders effectively placed after 5:00pm EST on May 17. The company adds that it will continue to evaluate pricing, noting that continued substantial price increases will, in light of the current market dynamics, be necessary in the effort to obtain sufficient revenue from the drug.

    | Jun. 13, 2013, 1:52 PM
  • Mar. 19, 2013, 12:00 PM

    Savient Pharmaceuticals (SVNT -9%) takes a hit after its Q4 beat expectations on a per share basis, but came up far short on revenue as net sales of Krystexxa posted a marginal 3% increase over Q3. Bottom line margins were also impacted by a cost of goods charge to Krystexxa inventory that the company doesn't believe will be sold prior to expiration.

    | Mar. 19, 2013, 12:00 PM | 1 Comment
  • Nov. 12, 2012, 9:10 AM
    Premarket gainers: TIE +43%. JEF +24%. MYRX +17%. CXS +15%. GILD +12%. CELG +10%. SVNT +7%. SQNM +7%. LUK +7%. RIMM +6%. NKTR +6%. STV +5%. DNDN +5%. CEL +5%. PCP +5%.
    Losers: CLVS -41%. STSI -20%. NBG -11%.
    | Nov. 12, 2012, 9:10 AM
  • Nov. 8, 2012, 9:10 AM
    Premarket gainers: DUSA +38%. MTSL +28%. USAT +15%. WLL +11%. ITMN +11%. SD +9%. QCOM +9%. THQI +8%. EZCH +7%. ALU +6%. MWW +7%. TTM +6%. DF +5%.
    Losers: CPRX -56%. BCRX -34%. PANL -25%. SVNT -19%. SGEN -11%. MNST -10%. CNQR -9%. TNK -9%. NBG -8%. PSTI -8%. MAKO -7%. WINI -6%. AUI -5%.
    | Nov. 8, 2012, 9:10 AM
  • Oct. 19, 2012, 9:10 AM
    Premarket gainers: SVNT +12%. RVBD +11%. CALL +7%. SNDK +7%.
    Losers: CBLI -20%. ATHN -11%. CMG -11%. MRVL -9%. PH -9%. ETFC -6%.
    | Oct. 19, 2012, 9:10 AM
  • Jul. 23, 2012, 2:40 PM

    Shares of Savient Pharmaceutical (SVNT +37%) spike higher following a favorable Court ruling granting both of Savient's motions in the lawsuit brought against the Company by Tang Capital Partners other convertible note holders. The Court ruled that there hasn't been any default on SVNT's convertible notes, nor can the plaintiff noteholders can't appoint a receiver because they have no standing. The Court has not yet decided on the plaintiff's claims for breach of fiduciary duty and waste.

    | Jul. 23, 2012, 2:40 PM
  • Jun. 6, 2012, 11:50 AM

    Savient Pharmaceuticals (SVNT +4.4%) says new data presented at the European League Against Rheumatism congress showed patients with refractory chronic gout also suffering from chronic kidney disease responded to treatment with its drug Krystexxa regardless of its baseline chronic kidney disease stage. The company is seeking approval for Krystexxa in Europe.

    | Jun. 6, 2012, 11:50 AM
  • May 9, 2012, 1:10 PM
    Savient Pharmaceuticals (SVNT -11%) takes a hit today after its Q1 results missed estimates. Total revenue actually jumped nearly 170% Y/Y, but bottom line margins were hit as expenses increased sharply. Much of the increase in expenses had to do with the commercialization and marketing of its new gout drug Krystexxa.
    | May 9, 2012, 1:10 PM
  • May 8, 2012, 12:30 PM

    Savient Pharmaceuticals (SVNT +18%) gets a pop after entering into secured arrangements with some of its creditors to restructure its debt load and head off recent criticisms of its financial position. The stock has been hit hard recently, after an earlier disclosure that it had been served with a creditor derivative action complaint alleging it was insolvent.

    | May 8, 2012, 12:30 PM
  • May 1, 2012, 2:19 PM

    Savient Pharmaceuticals (SVNT -33%) says in an SEC filing it's been served with a creditor derivative action complaint filed by Tang Capital Partners. The complaint alleges, among other things, that the company is insolvent. Savient believes the complaints are without merit, noting however, that it will consider financial transactions that will improve its overall balance sheet.

    | May 1, 2012, 2:19 PM | 1 Comment
  • Feb. 1, 2012, 10:48 AM
    Savient Pharmaceuticals (SVNT -12.6%) shares plunge after Dendreon (DNDN +4.6%) swipes its CEO, as John Johnson will take the helm at DNDN on June 30 after only one year at SVNT. Deutsche Bank says Johnson has a history of M&A and his fresh perspective might benefit DNDN's near-term strategy, noting his success in selling Imclone to Eli Lilly and attempts to sell SVNT.
    | Feb. 1, 2012, 10:48 AM | 1 Comment
  • Nov. 10, 2011, 1:41 PM
    Savient Pharmaceuticals (SVNT -6%) dips after JMP Securities cuts the shares to Market Underperform, citing limited growth potential for the company's gout treatment drug Krystexxa.
    | Nov. 10, 2011, 1:41 PM
  • Sep. 19, 2011, 1:40 PM
    Shares of Savient Pharmaceuticals (SVNT +7.5%) continue to climb after SEC filings show several key executives (I, II, III, IV) , including CEO John Johnson, purchased stock in the company last week.
    | Sep. 19, 2011, 1:40 PM | 2 Comments
  • Aug. 4, 2011, 11:32 AM

    Savient Pharmaceuticals (SVNT -25%) gets hammered after its Q2 results widely missed analysts' projections, as higher R&D, marketing and administrative expenses weighed on margins. Revenues were also down due to disappointing rollout sales of its new gout drug KRYSTEXXA.

    | Aug. 4, 2011, 11:32 AM
Company Description
Sector: Healthcare
Industry: Biotechnology
Country: United States